Use of a Belatacept-based Immunosuppression for Kidney Transplantation From Donors After Circulatory Death: A Paired Kidney Analysis.

ABSTRACT:

Background

Efficacy and safety of belatacept have not been specifically reported for kidney transplantations from donors after circulatory death.

Methods

In this retrospective multicenter paired kidney study, we compared the outcome of kidney transplantations with a belatacept-based to a calcineurin inhibitor (CNI)-based immunosuppression. We included all kidney transplant recipients from donors after uncontrolled or controlled circulatory death performed in our center between February 2015 and October 2020 and treated with belatacept (n = 31). The control group included the recipients of the contralateral kidney that were treated with CNI in 8 other centers (tacrolimus n = 29, cyclosporine n = 2).

Results

There was no difference in the rate of delayed graft function.

SUBMITTER: Eid R 

PROVIDER: S-EPMC11013701 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature